Table 3.

Treatment Characteristics in Total Patients Considering the Durability of the Response

	Patients with Durable Clinical Response (N=12)	Patients with Non-Durable Clinical Response (N=29)	P value
Dose modification, n (%)	8 (66.7)	15 (51.7)	0.497
Reasons *
Toxicity	12 (85.7)	24 (80.0)	1.000
Investigator decision	0 (0.0)	4 (12.3)	0.290
Clinical reasons	2 (14.3)	2 (6.7)	0.581
Time until dose modification, median months (IQR)	6.5 (2.5–11.8)	1.8 (0.5–5.3)	0.129
Adherence to treatment, n (%) **
Adherent	4 (100.0)	2 (66.7)	0.429
Non-adherent	0 (0.0)	1 (33.3)
Concurrent radiation therapy, n (%)			1.000
Yes	1 (8.3)	3 (10.3)
No	11 (91.7)	26 (89.7)
Oncologic surgery, n (%)			1.000
Yes	0 (0.0)	2 (6.9)
No	12 (100.0)	27 (93.1)

Notes: *The percentage in each group was calculated according to the total number of modifications (14 and 30 in patients with and without a long-term clinical response, respectively). **Adherence calculated over patients with active treatment at the moment of the study visit (4 and 3 in patients with and without a long-term clinical response, respectively).

Abbreviation: IQR, interquartile range.